Maplight Therapeutics (NASDAQ:MPLT) Raised to Strong-Buy at Leerink Partnrs

Maplight Therapeutics (NASDAQ:MPLT) was upgraded by analysts at Leerink Partnrs to a “strong-buy” rating in a report issued on Friday,Zacks.com reports.

A number of other research firms have also weighed in on MPLT. Wall Street Zen lowered shares of Maplight Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Morgan Stanley assumed coverage on Maplight Therapeutics in a research note on Friday. They set an “overweight” rating and a $34.00 target price for the company. Stifel Nicolaus assumed coverage on Maplight Therapeutics in a research report on Friday. They set a “buy” rating and a $28.00 target price on the stock. Leerink Partners started coverage on Maplight Therapeutics in a research note on Friday. They issued an “outperform” rating and a $30.00 price target on the stock. Finally, Jefferies Financial Group started coverage on Maplight Therapeutics in a report on Friday. They issued a “buy” rating and a $32.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating and four have issued a Buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $31.00.

Maplight Therapeutics Stock Performance

Maplight Therapeutics stock opened at $13.99 on Friday. Maplight Therapeutics has a one year low of $13.20 and a one year high of $20.86.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients.